Semaglutide reduced severity of a common liver disease in people with HIV, researchers reported
A reported finding in people with HIV adds to evidence that semaglutide acts on the liver beyond weight loss, a population not named in the drug's FDA-approved liver indication.
On March 5, 2024, researchers reported that semaglutide reduced the severity of a common liver disease in people living with HIV [1][2]. Semaglutide is the molecule sold as Ozempic, Wegovy and Rybelsus [1][2]. The finding adds to evidence that semaglutide affects the liver through pathways beyond weight loss alone [1].
The report describes the condition only as a common liver disease in that group and does not name the specific diagnosis [1][2]. Since then, no follow-up data from the study has been reported, and no findings from it have been added to the published approval timelines for semaglutide products [1][2].
What the HIV finding does and does not establish
Key details of the study have not been disclosed [1][2]. How many people were treated, what dose of semaglutide they received, how long they were followed, and whether the liver improvement held up after accounting for weight loss are all unreported [1][2].
Semaglutide has no approved use specific to people living with HIV [1][2]. Its approved uses are separate from that group: Ozempic is approved for type 2 diabetes and to reduce the risk of major cardiovascular events and worsening kidney disease in adults with type 2 diabetes, while Wegovy is approved for weight reduction, cardiovascular risk reduction, and noncirrhotic metabolic dysfunction-associated steatohepatitis, or MASH, in adults [2]. Rybelsus is approved for type 2 diabetes and cardiovascular risk reduction in adults with type 2 diabetes [2].
The liver approval that already exists
On August 15, 2025, the FDA granted Wegovy accelerated approval for noncirrhotic MASH with moderate to advanced liver fibrosis, consistent with stages F2 to F3, in adults [1]. That approval is based on improvement of MASH and fibrosis, and continued approval may depend on verification of clinical benefit in a confirmatory trial [1].
The Wegovy label states that the drug is thought to work in MASH through multiple pathways mediated by weight loss and other factors, not weight loss alone [1]. In November 2025, Novo Nordisk reported that Wegovy 2.4 mg was associated with liver health-related benefits not solely based on weight loss in adults with MASH and liver scarring [1].
Wegovy's approved MASH indication is written for adults generally and does not name people living with HIV as a separate group [1]. Whether the people in the HIV report would meet the approved MASH criteria, including the required fibrosis stage, has not been reported [1][2].
Safety information on the label
Wegovy and Ozempic carry a boxed warning for an increased risk of thyroid C-cell tumors [1][2]. Warnings and precautions include acute pancreatitis, acute gallbladder disease, low blood sugar, acute kidney injury, increased heart rate, and suicidal behavior and ideation [1][2]. Common side effects reported in 5 percent or more of patients include nausea, diarrhea, vomiting, constipation and abdominal pain [1][2]. The label advises against using Wegovy with another semaglutide-containing product or any other GLP-1 receptor agonist [1].
Why it matters for patients
Liver effects that appear independent of weight loss are part of why the FDA approved Wegovy for MASH with F2 to F3 fibrosis [1]. That means some patients with MASH and liver scarring already have an approved semaglutide option, regardless of this HIV report [1]. The HIV finding does not by itself change any approved use, and no HIV-specific liver indication has been granted for semaglutide [1][2].
For people living with HIV who are considering or taking a GLP-1 medication, several questions remain unanswered. It has not been reported whether HIV status changes how the liver responds to semaglutide, whether people with HIV need different liver monitoring while taking it, or whether semaglutide interacts with HIV medications [1][2]. The approval records do not address dosing or monitoring for that group [1][2]. MASH can also progress without symptoms, and the approved label ties treatment to a specific fibrosis range, which is determined by testing rather than by how a person feels [1].
What happens next
Wegovy's MASH approval is accelerated, which means the FDA expects a confirmatory trial to verify clinical benefit [1]. The date that trial will report has not been disclosed [1]. No additional results from the HIV liver report have been published since March 2024 [1][2].
Sources
Semaglutides.org provides information only, not medical advice. Talk to a licensed provider about your own care before making changes. Some telehealth links are affiliate links and are labeled where they appear.